This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

US HIFU Acquires European Distribution Rights Of The Sonablate® 500 Medical Device And Ownership Of The Sonatherm® 600 Medical Device

CHARLOTTE, N.C., May 28 /PRNewswire/ -- USHIFU, LLC (US HIFU), a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 (Sonablate) medical device, announces the acquisition of certain Misonix (Nasdaq: MSON) HIFU assets and European distribution rights. In addition, through its transaction with Misonix, US HIFU acquires the Sonatherm® 600 medical device, a laparoscopic HIFU system used to ablate certain soft tissues.

The acquisition of the Sonatherm 600 is a major step for US HIFU: it represents the company's first device with FDA clearance for commercialization in the U.S.

"Our intent has always been to continue building the HIFU device product pipeline, and acquiring the Sonatherm is a significant milestone in that process," said US HIFU's chief executive officer Steve Puckett, Jr. "The device has two FDA 510(k) clearances for soft tissue ablation. Post-market surveillance trials have already begun in Europe, and we plan to add clinical sites in the U.S. to study the Sonatherm 600 later this year."

In addition to US HIFU's plans for clinical evaluation of the Sonatherm 600 in Europe and the U.S., its plans for growing the Sonablate HIFU technology in Europe include rolling out state-of-the-art Sonablate 500 machines; infusing both capital and human resources to significantly increase access to Sonablate HIFU; expanding the base of European Sonablate users; and increasing the existing clinical data registry.

Sonablate HIFU for prostate cancer is a minimally invasive, targeted approach to treating the disease with precision-focused ultrasound energy that, when delivered, raises the temperature of the tissue in a matter of seconds, resulting in its destruction. The tissue throughout the prostate is ablated while structures outside the gland remain unharmed.

Members of US HIFU's management team are making preparations for a European road show whereby they will showcase the innovative feature upgrades to the Sonablate by giving a then-versus-now comparison. The team will also strategize with clinicians to tailor flexible, market-specific roll-out plans.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
MSON $12.43 1.14%
AAPL $128.46 -1.50%
FB $78.97 -1.79%
GOOG $558.40 0.53%
TSLA $203.34 -1.86%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs